Novel targeted anti-inflammatory therapies against known markers of inflammation in acute coronary syndromes have consistently failed to show significant clinical benefit in large phase 3 trials.
This review highlights that despite promising early data, targeted anti-inflammatory therapies for ACS have consistently failed to improve clinical outcomes in phase 3 trials.
The importance of inflammation and inflammatory pathways in atherosclerotic disease and acute coronary syndromes (ACS) is well established. The success of statin therapy rests not only on potently reducing levels of low-density lipoprotein cholesterol, but also on the many beneficial, pleiotropic effects statin therapy has on various inflammatory mechanisms in atherosclerotic disease, from reducing endothelial dysfunction to attenuating levels of serum C-reactive protein. Due to the growing awareness of the importance of inflammation in ACS, investigators have attempted to develop novel therapies against known markers of inflammation for several decades. Targeted pathways have ranged from inhibiting C5 cleavage with a high-affinity monoclonal antibody against C5 to inhibiting the activation of the p38 mitogen-activated protein kinase signaling cascades. In each of these instances, despite promising early preclinical and mechanistic studies and phase 2 trials suggesting a potential benefit in reducing post-MI complications or restenosis, these novel therapies have failed to show benefits during large, phase 3 clinical outcomes trials. This review discusses several examples of novel anti-inflammatory therapies that failed to show significant improvement on clinical outcomes when tested in large, randomized trials and highlights potential explanations for why targeted therapies against known markers of inflammation in ACS have failed to launch.
Rymer et al. (Tue,) conducted a review in Atherosclerotic disease and acute coronary syndromes. Novel anti-inflammatory therapies was evaluated. Novel targeted anti-inflammatory therapies against known markers of inflammation in acute coronary syndromes have consistently failed to show significant clinical benefit in large phase 3 trials.